Filing Details
Foghorn Therapeutics Inc. (NASDAQ:FHTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:FHTX
Foghorn Therapeutics Inc. (FHTX) Files Quarterly Report for Q0
Foghorn Therapeutics Inc. (NASDAQ:FHTX) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on November 09, 2026.
At publication ·
What changed
Foghorn Therapeutics Inc. (NASDAQ:FHTX) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Foghorn Therapeutics filed its Q0 quarterly report on November 09, 2026 with the SEC.
- The company's stock trades at $1.87 with a market capitalization of $252.8 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance and emerging trends.
Market Context
Foghorn Therapeutics Inc.'s stock currently trades at $1.87 with a market capitalization of $252.8M.
The 10-Q provides Foghorn Therapeutics Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Foghorn Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View FHTX Stock Page
Frequently Asked Questions
Where can I read FHTX's SEC filings?
Browse all filings on our FHTX SEC filings page.
What types of SEC filings does Foghorn Therapeutics Inc. file?
Public companies like Foghorn Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
